Helix BioPharma (TSE:HBP)
TSX:HBP
Want to see TSE:HBP full AI Analyst Report?
HBP Stock Chart & Stats
C$2.40
-C$0.03(-3.23%)
At close: 4:00 PM EST
C$2.40
-C$0.03(-3.23%)
Day’s Range― - ―
52-Week RangeC$0.78 - C$5.40
Previous CloseN/A
Volume518.00
Average Volume (3M)13.00K
Market Cap
C$144.35M
Enterprise ValueC$156.90M
Total Cash (Recent Filing)C$31.00K
Total Debt (Recent Filing)C$359.00K
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Jun 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding76,378,100
10 Day Avg. Volume29,165
30 Day Avg. Volume13,000
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)3.83
Price to Sales (P/S)0.00
P/FCF Ratio-15.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Equity BaseVery low leverage and a meaningful equity buffer reduce near-term solvency risk for a development-stage biotech. This capital structure gives management time to advance clinical programs without immediate debt pressure, supporting operational optionality over several quarters.
R&D-focused Pipeline StrategyA concentrated R&D portfolio centered on oncology allows the company to allocate scarce resources toward high-impact assets. For a biotech, disciplined portfolio management and clinical progress can create durable value drivers independent of short-term market moves.
Improving Cash Burn TrendReduced cash burn versus prior periods indicates management has tightened spending and improved capital efficiency. If sustained, lower burn extends runway and reduces near-term financing needs, strengthening the firm's ability to fund key clinical milestones.
Bears Say
No Revenue BaseAbsence of commercial revenue means the company depends entirely on financing and milestone events to continue operations. This structural lack of recurring cash inflows increases dilution and execution risk until a candidate reaches commercialization or generates licensing income.
Persistent Negative Cash FlowSustained negative free cash flow creates ongoing financing needs and exposes the company to capital-market access risk. Continued reliance on external funding can dilute shareholders and constrain long-term project selection if markets tighten.
Historical Balance Sheet VolatilityPrior episodes of negative equity signal that the company's capitalization has been fragile. Recurrence would undermine credibility with partners and investors, making it harder to secure favorable financings and potentially delaying clinical development timelines.
Helix BioPharma News
HBP FAQ
What was Helix BioPharma’s price range in the past 12 months?
Helix BioPharma lowest stock price was C$0.78 and its highest was C$5.40 in the past 12 months.
What is Helix BioPharma’s market cap?
Helix BioPharma’s market cap is C$144.35M.
When is Helix BioPharma’s upcoming earnings report date?
Helix BioPharma’s upcoming earnings report date is Jun 17, 2026 which is in 48 days.
How were Helix BioPharma’s earnings last quarter?
Helix BioPharma released its earnings results on Mar 16, 2026. The company reported -C$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.009.
Is Helix BioPharma overvalued?
According to Wall Street analysts Helix BioPharma’s price is currently Overvalued.
Does Helix BioPharma pay dividends?
Helix BioPharma does not currently pay dividends.
What is Helix BioPharma’s EPS estimate?
Helix BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Helix BioPharma have?
Helix BioPharma has 76,378,100 shares outstanding.
What happened to Helix BioPharma’s price movement after its last earnings report?
Helix BioPharma reported an EPS of -C$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.793%.
Which hedge fund is a major shareholder of Helix BioPharma?
Currently, no hedge funds are holding shares in TSE:HBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Helix BioPharma
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.
Technical Analysis
Satellos Bioscience
―
Arch Biopartners
―
Medicenna Therapeutics Corp
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―
Options Prices
Currently, No data available
---